EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review

Marina Romozzi, Antonio Munafò, Andrea Burgalassi, Francesco De Cesaris, Giulia Vigani, Claudia Altamura iD, Veronica Rivi, Simona Guerzoni, Paolo Calabresi, Bianca Raffaelli iD, Luigi Francesco Iannone

Headache: The Journal of Head and Face Pain · 2025-02 · 65 (2) · 342-352

DOI: 10.1111/head.14903 ↗

At a glance

Übersichtsarbeit in Headache: The Journal of Head and Face Pain, published online on 2025-01-17. Written by Marina Romozzi and 10 co-authors. Institution: Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy. Major MEDLINE topics: Antibodies, Monoclonal, Migraine Disorders, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists. Cited 35 times so far (Crossref); 73 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Antibodies targeting either the calcitonin gene–related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti‐CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect. However, differences in therapeutic targets, structure, and pharmacokinetic characteristics may influence their efficacy and safety differently. Therefore, in patients not achieving a clinically meaningful response with one anti‐CGRP antibody, switching to a different antibody may be a viable option. This review examines the pharmacological characteristics and distinctions among anti‐CGRP mAbs, highlighting their mechanisms of action and pharmacokinetic profiles, along with the clinical observational data of switching. Finally, we summarize suggestions from international guidelines.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalMigraine DisordersCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsDrug SubstitutionHumans

Author keywords

calcitonin gene–related peptidemonoclonal antibodiesswitch

Substances

Antibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
  • Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.
  • Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Headache and Neurosonology Unit, Fondazione Policlinico Campus Bio-Medico-Università Campus Bio-Medico Di Roma, Rome, Italy.

ORCID profiles: Claudia Altamura, Bianca Raffaelli

Cite

APA

Romozzi, M., Munafò, A., Burgalassi, A., De Cesaris, F., Vigani, G., Altamura, C., Rivi, V., Guerzoni, S., Calabresi, P., Raffaelli, B., & Iannone, L. F. (2025). Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review. Headache: The Journal of Head and Face Pain, 65(2), 342-352. https://doi.org/10.1111/head.14903

Vancouver

Romozzi M, Munafò A, Burgalassi A, De Cesaris F, Vigani G, Altamura C, et al. Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review. Headache: The Journal of Head and Face Pain. 2025;65(2):342-352. doi:10.1111/head.14903

BibTeX
@article{Romozzi2025,
  author = {Romozzi, Marina and Munafò, Antonio and Burgalassi, Andrea and De Cesaris, Francesco and Vigani, Giulia and Altamura, Claudia and Rivi, Veronica and Guerzoni, Simona and Calabresi, Paolo and Raffaelli, Bianca and Iannone, Luigi Francesco},
  title = {Pharmacological differences and switching among anti‐ CGRP monoclonal antibodies: A narrative review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  volume = {65},
  number = {2},
  pages = {342--352},
  doi = {10.1111/head.14903}
}
Start for free →